Antigenics’s AG-707 vaccine has shown positive results in a Phase I study to treat herpes simplex virus-2 (HSV-2).

The vaccine triggered a cellular immune response, stimulating the CD4+ and CD8+ T-cell responses needed to treat genital herpes, a sexually transmitted infection.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

In the four-arm Phase I trial, 35 HSV-2 seropositive patients were administered AG-707 with vaccine adjuvant QS-21, AG-707 alone, QS-21 alone, or placebo.

All patients who received AG-707 with QS-21 showed a statistically significant CD4+ T cell response to HSV-2 antigens and the majority (63%) demonstrated a CD8+ T cell response.

AG-707 is based on Antigenics’s heat shock protein platform technology. This study is the first to show that heat shock protein complexed to viral antigens induces an antigen-specific T-cell response in humans.

See Also:

Antigenics said the investigational drug has the potential to manage outbreaks and disease transmission in patients with genital herpes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.